Intercept Tumbles After FDA Rejects Liver Disease Treatment By Investing.com
2020-06-29
© Reuters. By Christiana Sciaudone Investing.com — Intercept Pharmaceuticals Inc . (NASDAQ:)shares tumbled 39%, to their lowest in seven years on Monday after the U.S. Food and Drug Administration said the benefits of its new liver disease drug are uncertain and don’t outweigh potential risks. The FDA’s Complete Response LetterRead More →